These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36827225)

  • 1. Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study.
    Fu EL; D'Andrea E; Wexler DJ; Patorno E; Paik JM
    Clin J Am Soc Nephrol; 2023 May; 18(5):592-601. PubMed ID: 36827225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults.
    Patorno E; Pawar A; Bessette LG; Kim DH; Dave C; Glynn RJ; Munshi MN; Schneeweiss S; Wexler DJ; Kim SC
    Diabetes Care; 2021 Mar; 44(3):826-835. PubMed ID: 33495295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative safety and cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in nursing homes.
    Riester MR; Zullo AR; Joshi R; Daiello LA; Hayes KN; Ko D; Kim DH; Munshi M; Berry SD
    Diabetes Obes Metab; 2024 Aug; 26(8):3403-3417. PubMed ID: 38779879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
    Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels.
    D'Andrea E; Wexler DJ; Kim SC; Paik JM; Alt E; Patorno E
    JAMA Intern Med; 2023 Mar; 183(3):242-254. PubMed ID: 36745425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts.
    Rebordosa C; Thomsen RW; Tave AK; Madsen M; Beachler DC; Martinez D; Garcia-Esteban R; Plana E; Tormos A; Farsani SF; Perez-Gutthann S; Pladevall-Vila M
    Diabetes Obes Metab; 2024 Apr; 26(4):1291-1304. PubMed ID: 38234181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk.
    Htoo PT; Paik JM; Alt E; Kim DH; Wexler DJ; Kim SC; Patorno E
    J Gerontol A Biol Sci Med Sci; 2023 Dec; 78(12):2426-2434. PubMed ID: 36866496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease.
    Milder TY; Stocker SL; Day RO; Greenfield JR
    Drug Saf; 2020 Dec; 43(12):1211-1221. PubMed ID: 33095409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
    Dave CV; Kim SC; Goldfine AB; Glynn RJ; Tong A; Patorno E
    Circulation; 2021 Feb; 143(8):770-779. PubMed ID: 33302723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Safety of Sodium-Glucose Cotransporter-2 Inhibitors in a Nationwide Veterans Health Administration Observational Cohort Study.
    Patil T; Cook M; Hobson J; Kaur A; Lee A
    Am J Cardiol; 2023 Aug; 201():281-293. PubMed ID: 37393731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong.
    Lui DTW; Tang EHM; Wu T; Au ICH; Lee CH; Woo YC; Tan KCB; Wong CKH
    Cardiovasc Diabetol; 2023 Feb; 22(1):40. PubMed ID: 36829226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Rigato M; Fadini GP; Avogaro A
    Diabetes Obes Metab; 2023 Oct; 25(10):2963-2969. PubMed ID: 37402697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease.
    Yen FS; Hwu CM; Liu JS; Wu YL; Chong K; Hsu CC
    Ann Intern Med; 2024 Jun; 177(6):693-700. PubMed ID: 38684099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals.
    Lin DS; Lee JK; Chen WJ
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2133-2145. PubMed ID: 33895840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.
    Xu Y; Boyle TA; Lyu B; Ballew SH; Selvin E; Chang AR; Inker LA; Grams ME; Shin JI
    J Gen Intern Med; 2024 May; 39(7):1112-1121. PubMed ID: 38191976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
    Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
    Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
    Dave CV; Schneeweiss S; Kim D; Fralick M; Tong A; Patorno E
    Ann Intern Med; 2019 Aug; 171(4):248-256. PubMed ID: 31357213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes.
    Paik JM; Tesfaye H; Curhan GC; Zakoul H; Wexler DJ; Patorno E
    JAMA Intern Med; 2024 Mar; 184(3):265-274. PubMed ID: 38285598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors.
    Qiu M; Ding LL; Zhang M; Zhou HR
    Diab Vasc Dis Res; 2021; 18(2):14791641211011016. PubMed ID: 33887983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.